Popat, R;
Brown, SR;
Flanagan, L;
Hall, A;
Gregory, W;
Kishore, B;
Streetly, M;
... Cavenagh, J; + view all
(2019)
Extended follow‐up and the feasibility of Panobinostat maintenance for patients with Relapsed Multiple Myeloma treated with Bortezomib, Thalidomide, Dexamethasone plus Panobinostat (MUK six open label, multi‐centre phase I/II Clinical Trial).
British Journal of Haematology
, 185
(3)
pp. 573-578.
10.1111/bjh.15551.
Preview |
Text
Yong_MUK-6 Extended Follow-up and maintenance_BJH_revised clean.pdf - Accepted Version Download (488kB) | Preview |
| Type: | Article |
|---|---|
| Title: | Extended follow‐up and the feasibility of Panobinostat maintenance for patients with Relapsed Multiple Myeloma treated with Bortezomib, Thalidomide, Dexamethasone plus Panobinostat (MUK six open label, multi‐centre phase I/II Clinical Trial) |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1111/bjh.15551 |
| Publisher version: | https://doi.org/10.1111/bjh.15551 |
| Language: | English |
| Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. |
| Keywords: | myeloma, clinical trials, myeloma therapy |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Haematology |
| URI: | https://discovery-pp.ucl.ac.uk/id/eprint/10102579 |
Archive Staff Only
 |
View Item |
